OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+51.73%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$361M
AUM Growth
+$361M
(+35%)
Cap. Flow
+$26.3M
Cap. Flow
% of AUM
7.29%
Top 10 Holdings %
Top 10 Hldgs %
42.47%
Holding
67
New
20
Increased
17
Reduced
12
Closed
14
Top Buys
| 1 |
uniQure
QURE
|
$12.2M |
| 2 |
Ascendis Pharma
ASND
|
$11.2M |
| 3 |
NVTA
Invitae Corporation
NVTA
|
$10.3M |
| 4 |
Catalyst Pharmaceutical
CPRX
|
$9.31M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$7.7M |
Top Sells
| 1 |
LOXO
Loxo Oncology, Inc
LOXO
|
$24.5M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$13.6M |
| 3 |
AMRN
Amarin Corp
AMRN
|
$12.6M |
| 4 |
Xencor
XNCR
|
$6.51M |
| 5 |
Sangamo Therapeutics
SGMO
|
$5.74M |
Sector Composition
| 1 | Healthcare | 93.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Codexis
CDXS
$246M
| $30.3M | 8.39% | 1,475,000 -275,000 | -16% | -$5.65M |
|
2
Axogen
AXGN
$743M
| $23.2M | 6.41% | 1,100,000 -200,000 | -15% | -$4.21M |
|
|
EPZM
3
DELISTED
Epizyme, Inc
EPZM
| $16.9M | 4.68% | 1,365,000 +240,000 | +21% | +$2.97M |
|
4
Avalo Therapeutics
AVTX
$122M
| $13.4M | 3.72% | 2,300,000 +114,464 | +5% | +$668K |
|
|
AMRN
5
Amarin Corp
AMRN
$311M
| $13.4M | 3.71% | 645,000 -605,000 | -48% | -$12.6M |
|
|
6
uniQure
QURE
$896M
| $12.2M | 3.39% | +205,000 | New | +$12.2M |
|
|
7
Ascendis Pharma
ASND
$11.8B
| $11.2M | 3.1% | +95,000 | New | +$11.2M |
|
8
TG Therapeutics
TGTX
$4.65B
| $11M | 3.04% | 1,366,062 +816,062 | +148% | +$6.56M |
|
|
BOLD
9
DELISTED
Audentes Therapeutics, Inc
BOLD
| $10.9M | 3.03% | 280,000 +30,000 | +12% | +$1.17M |
|
10
FibroGen
FGEN
$47.8M
| $10.9M | 3.01% | 200,000 | – | – |
|
|
CMTA
11
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
| $10.4M | 2.89% | 400,130 +250,130 | +167% | +$6.53M |
|
|
BPMC
12
DELISTED
Blueprint Medicines
BPMC
| $10.4M | 2.88% | 130,000 -170,000 | -57% | -$13.6M |
|
|
NVTA
13
DELISTED
Invitae Corporation
NVTA
| $10.3M | 2.85% | +440,000 | New | +$10.3M |
|
|
14
Catalyst Pharmaceutical
CPRX
$2.52B
| $9.31M | 2.58% | +1,825,000 | New | +$9.31M |
|
15
Harrow
HROW
$1.44B
| $8.96M | 2.48% | 1,800,000 +78,000 | +5% | +$388K |
|
16
Dianthus Therapeutics
DNTH
$759M
| $8.4M | 2.33% | 510,000 +5,000 | +1% | +$82.4K |
|
17
PTC Therapeutics
PTCT
$3.92B
| $8.05M | 2.23% | 213,800 +23,800 | +13% | +$896K |
|
|
DCPH
18
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $7.89M | 2.19% | 340,000 | – | – |
|
|
MRTX
19
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $7.7M | 2.13% | +105,000 | New | +$7.7M |
|
20
Ocular Therapeutix
OCUL
$2.12B
| $7.54M | 2.09% | +1,900,000 | New | +$7.54M |
|
|
CBAY
21
DELISTED
Cymabay Therapeutics
CBAY
| $7.3M | 2.02% | 550,000 -175,000 | -24% | -$2.32M |
|
|
ODT
22
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $7.19M | 1.99% | 325,000 +276,000 | +563% | +$6.1M |
|
23
Cytokinetics
CYTK
$4.23B
| $6.88M | 1.9% | +850,000 | New | +$6.88M |
|
|
TCDA
24
DELISTED
Tricida, Inc. Common Stock
TCDA
| $6.37M | 1.76% | 165,000 +42,000 | +34% | +$1.62M |
|
25
Eton Pharmaceutcials
ETON
$464M
| $6.12M | 1.69% | 764,773 +241,773 | +46% | +$1.93M |
|